about
CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.The current perspective of low-grade myelodysplastic syndrome in children.Chemotherapy for a child with relapsed acute myeloid leukemia complicated with persistent hepatitis C virus infection.Risk Factors for Hospital-acquired Clostridium difficile Infection Among Pediatric Patients With Cancer.Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group.Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemiaNo impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.Bullous exudative retinal detachment due to infiltration of leukemic cells in a child with acute lymphoblastic leukemia.The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse.Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99).RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro.Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese.Risk factors for psychological and psychosomatic symptoms among children with malignancies.Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).A Cytokine-Based Diagnostic Program in Pediatric Aplastic Anemia and Hypocellular Refractory Cytopenia of Childhood.Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.Scurvy: From a Selective Diet in Children with Developmental Delay.Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials.Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide.Cervical ultrasound and computed tomography of Kawasaki disease: Comparison with lymphadenitis.Significance of CD66c expression in childhood acute lymphoblastic leukemia.The landscape of somatic mutations in Down syndrome-related myeloid disorders.Intellectual development after treatment in children with acute leukemia and brain tumor.Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.Hazards of early BCG vaccination: BCGitis in a patient with chronic granulomatous disease.Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin.Aggressive Transformation of Juvenile Myelomonocytic Leukemia Associated with Duplication of Oncogenic KRAS due to Acquired Uniparental DisomyDuplication of F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastomaThe utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 studyDown syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia[Myelodysplastic syndrome in childhood and juvenile myelomonocytic leukemia]Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classificationEvaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12)Haploidentical hematopoietic cell transplantation for disseminated Ewing sarcoma
P50
Q33398560-BB224890-641C-414F-8DFA-689D63CEB3FEQ34478851-DF4640CA-A32D-4D22-B629-E45600BCE2B5Q38255276-0C937CA3-F997-4B4C-ACE9-CD0379A3CB50Q38759371-26ADCF90-5E2B-4C5E-81BA-953FDE9E371BQ40134005-BF83ED91-0D10-4DD0-B64A-DFA3505C88E9Q40400492-61F7BEC6-ED85-4C90-A8D8-861163C359D1Q40518805-B0BB963A-8F0E-496E-A912-3BED49958283Q40928836-C5146F83-7D9C-47E2-AE25-4016A8A8D2E3Q41850026-0E9553D5-6477-41A7-97D4-5DB8471A7C63Q42242801-203C5018-8CE5-4FA2-A642-0F5709226B61Q42908267-04315F77-0814-4497-9CDE-4FF01920952BQ43273766-703E3ADD-51B8-4B59-B27E-9EFA12456972Q43290431-D9DEC1CA-9E8D-4A34-878A-0455722C7B6CQ45212012-BDC46AAC-4E46-44E9-B129-EE6615364136Q46620918-8A4CF9C7-C9A0-419F-8E53-A9468521C364Q47559245-16C87C21-45B3-49E9-8B1A-8AAC5A88743BQ47654469-59867F31-D984-450E-930F-54F484D6D39BQ47752623-EB53F4AA-6CDA-4DDB-8B85-67C0ED91C1E8Q48005356-43EE6724-2769-4D21-8302-E16B88E8B25FQ50282618-89962A3F-4C03-4FA2-AA03-348C61D1CD7DQ50454150-16B55EF4-0E4A-4368-8F94-13C7367F74BCQ50498112-B3CE054E-205A-4C4F-937C-869F90DBA5EAQ51074196-9B1C0C2E-026A-4E0D-AEBF-8539611CBB4EQ52626221-9EA86726-3A66-41D6-8B43-7D3BD246A936Q52982223-8BABB04F-6BE0-45A2-8CB0-FDC3A99F4B32Q52983514-FC3E466D-FFF8-4D16-B7EF-A6464DBA90E8Q53083090-4FFC6530-23DE-42DC-890D-FBD2BD30452FQ53089292-C7F978FB-7F07-4D39-8229-66AABF5D78B1Q53157083-852FA8CE-1BC0-4993-A17E-BDA567216D98Q53268701-EA56B8F5-2087-47AF-9AA4-D819CE169283Q53479509-C6CECB1C-00D0-45B1-AD72-0C27DB280ABEQ53722710-34FEAF23-73FE-4560-8BAB-2EE21026E5D1Q57518114-E3CD4D7E-FCC7-443C-B8EF-CF22F7BD036BQ64234454-B2F5F0FD-7C45-4130-A29C-F141C8A8C7B7Q83259656-20540850-9E31-48B1-A0A7-443580EDCA98Q84784177-93777120-7D32-44C0-BFF1-7DF00075EB84Q85384922-7C20AB2B-6330-4DF7-B0CA-581706FD8ED5Q88012204-6E5D7212-6AAD-4C99-BDB4-64B44A79B9DAQ89061271-D0949801-9830-4BCA-90BD-3C1EAC9B0E2FQ89349376-899947C8-1C7B-4A04-BCE9-2BE70C5AA153
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-9446-9568
@en
name
Daisuke Hasegawa
@ast
Daisuke Hasegawa
@en
Daisuke Hasegawa
@es
Daisuke Hasegawa
@nl
Daisuke Hasegawa
@sl
type
label
Daisuke Hasegawa
@ast
Daisuke Hasegawa
@en
Daisuke Hasegawa
@es
Daisuke Hasegawa
@nl
Daisuke Hasegawa
@sl
prefLabel
Daisuke Hasegawa
@ast
Daisuke Hasegawa
@en
Daisuke Hasegawa
@es
Daisuke Hasegawa
@nl
Daisuke Hasegawa
@sl
P106
P21
P31
P496
0000-0002-9446-9568